{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:40Z","timestamp":1765814680838,"version":"3.48.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>\n                    This study evaluates the consistency between the centromere AC-3 immunofluorescence pattern and the anti-centromere protein B (anti-CENP-B) antibody test results and analyzes differences in the positive rates of potential related diseases with anti-centromere antibody (ACA) positivity. A retrospective collection of antinuclear antibody fluorescent patterns and anti-CENP-B test data from inpatients at Maanshan People\u2019s Hospital between February 2022 and February 2024 was performed. The consistency of different methods was evaluated using the kappa test and overall consistency calculation. Subsequently, the main diagnostic information of patients with ACA positivity was extracted, and the positive rates of ACAs in potential related diseases were analyzed. A total of 7893 patients were tested for both antinuclear antibody patterns and anti-CENP-B antibodies. Among them, 3959 patients were tested for ACAs using indirect immunofluorescence and Western blotting; 3936 patients were tested by indirect immunofluorescence and multiplex flow cytometric immunoassay. The consistency analysis showed that the\n                    <jats:italic toggle=\"yes\">kappa<\/jats:italic>\n                    coefficients for both comparisons were &gt;0.81, and the overall consistency was &gt;99%, indicating that the AC-3 pattern and anti-CENP-B antibody test results were almost completely consistent. ACA positivity was observed in a variety of autoimmune diseases, with systemic sclerosis showing the highest positive rate (41.18%, 95% confidence interval: 32.12%\u201350.88%), followed by primary biliary cholangitis (40.00%, 95% confidence interval: 11.76%\u201376.93%). The positive rates of ACAs in 16 diseases were significantly higher than those in healthy control populations. There was almost complete consistency between the AC-3 pattern and the anti-CENP-B antibody test, suggesting that CENP-B is the main target antigen of the AC-3 pattern. ACA positivity was observed in various autoimmune diseases, especially systemic sclerosis and primary biliary cholangitis. This study offered useful insights for both basic and clinical investigations of ACAs.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046425","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:01:05Z","timestamp":1765814465000},"page":"e46425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the concordance between centromere AC-3 immunofluorescence pattern and anti-centromere protein-B antibody, and analyzing clinical correlates of dual positivity: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5044-0421","authenticated-orcid":false,"given":"Song","family":"He","sequence":"first","affiliation":[{"name":"Department of Immunology, Maanshan Center for Clinical Laboratory, Maanshan, China"},{"name":"Department of Clinical Laboratory, Maanshan People\u2019s Hospital, Maanshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maanshan Center for Clinical Laboratory, Maanshan, China"},{"name":"Department of Clinical Laboratory, Maanshan People\u2019s Hospital, Maanshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Maanshan People\u2019s Hospital, Maanshan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maanshan Center for Clinical Laboratory, Maanshan, China"},{"name":"Department of Clinical Laboratory, Maanshan People\u2019s Hospital, Maanshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Hai","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maanshan Center for Clinical Laboratory, Maanshan, China"},{"name":"Department of Clinical Laboratory, Maanshan People\u2019s Hospital, Maanshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"1421528","DOI":"10.3389\/fimmu.2024.1421528","article-title":"Dual role of autoantibodies to heat shock proteins in autoimmune diseases.","volume":"15","author":"Tukaj","year":"2024","journal-title":"Front Immunol"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"109740","DOI":"10.1016\/j.intimp.2023.109740","article-title":"Therapeutic potential of tolerance-based peptide vaccines in autoimmune diseases.","volume":"116","author":"Yu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41582-023-00776-4","article-title":"Origins and immunopathogenesis of autoimmune central nervous system disorders.","volume":"19","author":"Ramanathan","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11906-019-0914-2","article-title":"Autoimmune disease-associated hypertension.","volume":"21","author":"Wolf","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"103236","DOI":"10.1016\/j.autrev.2022.103236","article-title":"Autoimmune pre-disease.","volume":"22","author":"Bieber","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R6-20251215","first-page":"2152","article-title":"An overview of autoimmune diseases and autoantibodies.","volume":"38","author":"Qian","year":"2022","journal-title":"Chin J Immunol"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/cells12060918","article-title":"Molecular mechanisms in autoimmune thyroid disease.","volume":"12","author":"Vargas-Uricoechea","year":"2023","journal-title":"Cells"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease.","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1083\/jcb.110.5.1475","article-title":"CENP-B: a major human centromere protein located beneath the kinetochore.","volume":"110","author":"Cooke","year":"1990","journal-title":"J Cell Biol"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.1780230602","article-title":"Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.","volume":"23","author":"Tan","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/03009740600588376","article-title":"Anti-centromere antibodies in patients with systemic lupus erythematosus.","volume":"35","author":"Respaldiza","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3904\/kjim.2021.467","article-title":"Is the anti-centromere antibody a marker for a distinct subset of polyautoimmunity in Sj\u00f6gren\u2019s syndrome?","volume":"36","author":"Lee","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s12328-020-01092-w","article-title":"Development of anti-centromere antibody-positive autoimmune hepatitis after childbirth.","volume":"13","author":"Saito","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40744-018-0126-2","article-title":"Clinical and immunological features of anti-centromere antibody-positive primary Sj\u00f6gren\u2019s syndrome.","volume":"5","author":"Tsukamoto","year":"2018","journal-title":"Rheumatol Ther"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/annrheumdis-2020-218881","article-title":"Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.","volume":"80","author":"Kajio","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R16-20251215","first-page":"272","article-title":"Overlap of ACA-positive systemic sclerosis and Sj\u00f6gren\u2019s syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.","volume":"31","author":"Baldini","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20251215","first-page":"1088","article-title":"Clinical and immunological features of primary Sj\u00f6gren\u2019s syndrome patients with positive anti-centromere protein B antibody.","volume":"55","author":"Meng","year":"2023","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/23971983231215470","article-title":"Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.","volume":"9","author":"Philip","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12026-021-09233-0","article-title":"How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.","volume":"69","author":"von M\u00fchlen","year":"2021","journal-title":"Immunol Res"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0010-4825(92)90063-S","article-title":"Measures of clinical agreement for nominal and categorical data: the kappa coefficient.","volume":"22","author":"Cyr","year":"1992","journal-title":"Comput Biol Med"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis.","volume":"47","author":"Kruskal","year":"1952","journal-title":"J Am Stat Assoc"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1002\/imt2.85","article-title":"OmicStudio: a composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication.","volume":"2","author":"Lyu","year":"2023","journal-title":"Imeta"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5339\/qmj.2023.sqac.28","article-title":"Anti-centromere antibodies and associated autoimmune diseases.","volume":"2023","author":"Hanae","year":"2023","journal-title":"Qatar Med J"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"1256526","DOI":"10.3389\/fimmu.2023.1256526","article-title":"Complex patterns on HEp-2 indirect immunofluorescence assay in a large sample referred for anti-cell autoantibodies detection.","volume":"14","author":"Santos","year":"2024","journal-title":"Front Immunol"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease.","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"R29-20251215","first-page":"205","article-title":"Sex-based differences in autoimmune diseases.","volume":"52","author":"Ortona","year":"2016","journal-title":"Ann Ist Super Sanita"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"604000","DOI":"10.3389\/fimmu.2020.604000","article-title":"Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics.","volume":"11","author":"Shepherd","year":"2021","journal-title":"Front Immunol"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/03009740802116190","article-title":"Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies.","volume":"37","author":"Takada","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis.","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis.","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"1184252","DOI":"10.3389\/fimmu.2023.1184252","article-title":"Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"R35-20251215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R36-20251215","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12890-023-02562-w","article-title":"Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease.","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Pulm Med"},{"key":"R37-20251215","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/mr\/roab051","article-title":"Mast cells can produce transforming growth factor \u03b21 and promote tissue fibrosis during the development of Sj\u00f6gren\u2019s syndrome-related sialadenitis.","volume":"32","author":"Kaieda","year":"2022","journal-title":"Mod Rheumatol"},{"key":"R38-20251215","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","article-title":"REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A).","volume":"78","author":"Frangou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R39-20251215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/17476348.2022.2089116","article-title":"Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies.","volume":"16","author":"Diesler","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"R40-20251215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2334\/josnusd.22-0231","article-title":"Importance of anti-centromere antibodies in the diagnosis of Sj\u00f6gren\u2019s syndrome.","volume":"64","author":"Kitagawa","year":"2022","journal-title":"J Oral Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:01:11Z","timestamp":1765814471000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":39,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046425","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-07-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}